Kristin Willfond
Family Medicine · Shelbyville, INNPI 1801283536
Payments from drug & device makers
Across 82 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$401
- Novo Nordisk$194
- AstraZeneca$120
- Axsome Therapeutics, Inc.$119
- Roche Diagnostics Corporation$90
- GSK$73
- plus $459 from 13 others
What the payments were for
- Food & beverage$1,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $401 |
| Novo Nordisk | 12 | $194 |
| AstraZeneca | 8 | $120 |
| Axsome Therapeutics, Inc. | 7 | $119 |
| Roche Diagnostics Corporation | 1 | $90 |
| GSK | 5 | $73 |
| Lilly USA, LLC | 5 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Astellas Pharma US Inc | 4 | $63 |
| Pfizer | 2 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Merck | 1 | $19 |
| Amgen | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
How this compares
$1,455 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 73 | $81,002 |
| OzempicSemaglutide | 52 | $50,523 |
| JardianceEmpagliflozin | 20 | $29,407 |
| VraylarCariprazine Hcl | 16 | $24,490 |
| VascepaIcosapent Ethyl | 26 | $14,835 |
| EliquisApixaban | 17 | $13,369 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $12,355 |
| Spiriva RespimatTiotropium Bromide | 16 | $10,369 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,316 |
| Aripiprazole | 27 | $9,719 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 25 | $7,712 |
| LinzessLinaclotide | 13 | $6,911 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,937 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 21 | $4,622 |
| Gabapentin | 77 | $3,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $67 | $81,00273 claims |
| Novo NordiskOzempic | $194 | $50,52352 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $25 | $39,77636 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Arexvy, Shingrix | $73 | $35,00578 claims |
| AbbVieVraylar, Linzess | $401 | $31,40129 claims |
| PfizerEliquis | $45 | $13,36917 claims |
| AstraZenecaSymbicort | $120 | $4,93713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Shelbyville
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.